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Purpose: The purpose of this study was to determine whether the hemodynamic 
consequences of extracranial carotid disease correlate with the risk of subsequent cerebral 
infarction. 
Methods: In 95 patients with symptoms who had greater than or equal to 70% stenosis (31 
patients) or who had occlusion (64 patients) of the ipsilateral carotid artery, cerebral blood 
flow was measured by the stable xenon/computed tomography technique both at baseline 
and after vasodilatory challenge with intravenous acetazolamide. Patients were stratified 
into group 1, 43 patients with no more than a 5% decrease in flow in any vascular territory, 
and group 2, 52 patients with greater than a 5% decrease in one or more vascular territories 
after an acetazolamide challenge. 
Results: In group 2, 15 (28.9%) of 52 patients had a new stroke, but only one (2.3%) of 
43 patients in group i did (p = 0.0005). Of patients with total carotid occlusion 10 (26%) 
of 38 in group 2 and none (0%) of 26 in group i had a new stroke (p = 0.003). Of patients 
with greater than or equal to 70% stenosis, five (36%) of 14 in group 2 and only one (6%) 
of 17 in group 1 had a stroke (p = 0.067). 
Conclusion: The loss of cerebral reactivity in patients with symptoms who had greater than 
or equal to 70% carotid stenosis or occlusion is an important predictor of impending 
cerebral infarction. (J VAse SURG 1995;21:338-45.) 
The risk of stroke is high in patients with 
symptomatic carotid artery occlusive disease 
(CAOD). In the North American Symptomatic 
Carotid Endarterectomy Trial a cumulative risk of  
ipsilateral stroke of 26% was seen at 2 years in 
patients with greater than or equal to 70% diameter 
stenosis who had not undergone operation and were 
receiving the best medical therapy. 1 On the other 
hand 74% of the patients in North American 
Symptomatic Carotid Endarterectomy Trial did not 
have a stroke in that time interval, and it remains 
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unclear which additional risk factors account for the 
development of  cerebral infarction. The ability to 
further stratify patients with hemodynamically sig- 
nificant CAOD into very high- or low-risk groups 
would be an important clinical advantage. 
It has long been recognized that CAOD may 
produce stroke either on an atheroembolic or isch- 
emic hemodynamic basis, and it is not always possible 
to determine the cause once infarction has occurred. 
Since the early 1950s a focus has been placed on em- 
bolic events as the primary explanation for most cere- 
bral ischemic events, and surprisingly modest atten- 
tion has been paid to the effect of CAOD on intra- 
cranial hemodynamics in individual patients and on 
the correlation of those hemodynamic consequences 
with the risk of  irreversible cerebral ischemia. 24 
The development and validation of  stable xenon 
computed tomography (Xe/CT) cerebral blood flow 
(CBF) mapping has offered a valuable and easily 
accessible technique for measuring CBF. s'6 A hard- 
ware and software package for performing Xe/CT 
CBF mapping is now available for most CT scanners. 
Normal mixed cortical CBF (averaged gray and 
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Fig. 1. Xenon/CT CBF study. A and C represent regular baseline CT images for density" 
comparison and anatomic correlation. Blood flow maps prior to and after the administration of
ACZ are shown in B and D respectively. After ACZ, CBF is reduced primarily in the right 
middle cerebral artery territory. Color key shows CBF in cc/100gm/min. Numbers in B and D 
indicate mean CBF values in the relevant regions of interest (circled areas). (Reproduced with 
permission from Yonas et al. J Neurosurg 1993;79:4:84.) 
white matter) is approximately 50 to 55 ml/100 gm 
brain tissue/min. 7 However, this baseline value is 
variable and can be decreased as a result of either 
decreased supply or demand. Because compromised 
cerebral hemodynamics are associated with maxi- 
mum vasodilatation, CBF response to a vasodilatory 
challenge should provide a better assessment of 
vascular reserves or reactivity. Acetazolamide (ACZ) 
(Diamox) induces maximal cerebral vasodilatation 
caused by tissue acidosis,  The normal response is a 
significant (20% to 40%) increase in CBF in all 
vascular territories. Although CBF may change little 
in areas of basal vasodilatation with moderate collat- 
eral compromise, it may drop in territories with 
severe compromise of collaterals representing a
"steal" phenomenon. ACZ may be contraindicated in 
patients with cardiovascular instability, renal or 
hepatic insufficiency, or a history of allergy to sulfa 
drugs. 
METHODS 
CBF was measured with the stable Xe/CT CBF 
technique described by Gur et al. s Baseline flow 
values were obtained first, and the study was then 
repeated after a 20-minute washout period that was 
done after 1 gm ACZ was intravenously adminis- 
tered. 
Serial CT scatming was performed at two predes- 
ignated levels during the cerebral uptake phase of 
stable xenon gas, which the patients breathed at a 
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Table I. Summary of new strokes 
Territory of least reactivity 
Age Medical Degree of New stroke 
Stroke (yrs) Sex history vessel disease Territory Reactivity territory 
Group 1 
59 M TIA R arm/leg weakness Stenosis L ICA R ACA 15.8 L ACA 
Aphasia 
Group 2 
65 M TIA L armfleg weakness Stenosis R ICA L ACA - 7.9 R MCA 
L facial weakness 
L body numbness 
Slurred words 
58 M TIA L facial weakness Occluded R ICA R MCA - 17.3 R MCA 




58 M STR Bilateral arm/leg Occluded Bilat ICA R ACA - 8.5 I~. MCA 
Bilateral body numbness 
Unable to speak 
L hearing loss 
72 F TIA L vision loss Stenosis L ICA L ACA - 29.2 L ACA 
77 F STR R arm/leg weakness Occluded L ICA L MCA - 5.6 L MCA 
Aphasia 
55 M STR L arm/leg weakness Stenosis R ICA R MCA - 17.5 R MCA 
L facial weakness 
64 F TIA Bilateral arm/leg weakness Occluded R ICA R ACA - 29.9 R MCA 
Bilateral body numbness 
Balance problems 
Fainting 
71 M TIA L arm/leg weakness Stenosis R ICA R MCA - 18.4 R MCA 
L facial weakness 
Aphasia 
Memory impairment 
L hearing loss 
76 M STR L arm/leg weakness Occluded R ICA R MCA - 31.8 R MCA 
Facial weakness 
Slurred words 
60 M STR Bilateral arm/leg weakness Occluded R ICA R PCA - 8.6 R hemisphere 
Bilateral facial weakness 
Bilateral body numbness 
L eye vision loss 
Slurred words 
71 M STR R arm/leg weakness Occluded bilateral ICA R MCA - 8.2 R hemisphere 
K body numbness 
Aphasia 
40 M TIA L facial weakness Occluded R ICA R ACA - 26.7 R hemisphere 
Slurred words 
75 F TIA L arm/leg weakness Stenosis bilateral ICA R PCA - 7,9 L hemisphere 
L facial weakness 
L body numbness 
59 M STR R eye vision loss Occluded L ICA R ACA - 13.8 R PCA 
76 F TIA L arm/leg weakness Occluded R ICA R ACA - 67.9 L hemisphere 
L body numbness 
Reactivity, percent change in flow from baseline study to post-acetazolamide study; M, male; F, female; T/A, transient ischemic attack; 
STR, stroke; L, left; R, right; ICA, internal carotid artery; ACA, anterior cerebral artery territory; MCA, middle cerebral artery territory; 
PCA, posterior cerebral artery territory. 
concentration f 33% for 4.5 minutes (Fig. 1). Level 
1 was at the basal ganglia, and level 2 was approxi- 
mately 2 cm cephalad at the level of the centrum 
semiovale. Stable (nonradioactive) xenon gas has an 
atomic number of 54, is radiodense, is lipid-soluble, 
and rapidly and freely diffuses across the blood brain 
barrier. With the use of equations based on the Fick 
principle as modified by Kety, 9 CBF was calculated 
and reported for each voxel (1 x 1 x 10 mm) based 
on the rate of change of CT density and the 
concurrent arterial curve obtained irectly from the 
end tidal measurement of xenon concentration by 
JOURNAL OF VASCULAR SURGERY 
Volume 21, Number 2 Webster et al. 341 
0.9  ~ o ~ v° 1 UJ -I 60 
~o8 ~ 






n,, 0.5 I -  
0.4  GROUP I GROUP II [ 
0.3 . . . . . . . . .  ' . . . .  I . . . .  I . . . .  I . . . .  I . . . .  I 
0 5 10 15 20 25 30 35 
MONTHS 
Fig. 2. Cumulative stroke free survival by life table 
method for Groups I and II. p = 0.0004. 
thermoconductivity. Contiguous 2 cm diameter cir- 
cular regions of interest were placed around the 
cortical mantle on each of the two levels. Regions of 
interest encompassed approximately 314 voxels. The 
CBF values for each vascular territory corresponding 
to the anterior, middle, and posterior cerebral artery 
distribution were calculated by averaging the three to 
six regions of interest in each territory on each level 
(Fig. 1, B and D). The change in CBF that occurred 
after the administration of ACZ was computed for 
each of the 12 vascular territories per study. Terri- 
tories that included more than 50% infarction 
demonstrated on CT were excluded from analysis. 
The records of patients with symptomatic CAOD 
who had undergone Xe/CT CBF mapping before and 
after ACZ administration at the University of Pitts- 
burgh Medical Center were reviewed retrospectively. 
In compliance with our Institutional Review Board 
guidelines the initial individual patient contact and 
consent was obtained by a mailed request. All 
patients had symptoms of transient ischemic attacks 
or moderate nondisabling stroke and an ipsilateral 
carotid artery stenosis greater than 70% or occlusion 
confirmed by angiography. Patients were contacted 
immediately after consent, if the CBF study had been 
completed more than 6 months previously. Other- 
wise they were contacted 6 months after the CBF 
study. Subsequent follow-up information was then 
obtained at 6-month intervals. Patients were ex- 
cluded because of inadequate follow-up examination 
or technically poor studies. Patients who underwent 
cerebrovascular p ocedures before completion of a 
12-month follow-up period were also excluded• 
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Fig. 3. CBF values in cc/100gm/min for each of the 95 
patients depicted before and after ACZ challenge in the 
territory of least reactivity. Points above (to the left) of the 
line represent patients who had no drop in CBF. Points 
below (to the right) of the line represent patients with a 
decrease in CBF in one or more territories. Patients who 
sustained a stroke are depicted with a closed symbol. 
Patients who remain asymptomatic are depicted with open 
symbols. 
to the onset of a new stroke or cerebrovascular 
reconstruction more than 12 months after the CBF 
determination. New strokes were confirmed with a 
CT scan without contrast enhancement compared 
with initial CT studies. Patients who had persistent 
hemispheric neurologic deficits were also classified as 
having had a new stroke. Of  the 95 patients who 
qualified for the study, 31 patients had ipsilateral 
carotid stenosis greater than or equal to 70%, and 64 
patients had total carotid occlusion. Patient 
follow-up periods ranged from 0 to 62 months with 
a mean of 19.6 months. 
Patients were stratified into two groups of vas- 
cular reactivity depending on the CBF response to 
ACZ. Group 1 (43 patients) had no more than a 5% 
decrease in any vascular territory after ACZ chal- 
lenge, and group 2 (52 patients) had a decrease of 
more than 5% in at least one vascular territory after 
vasodilatory challenge. Although the use of a 5% 
decrease as a breakpoint is somewhat arbitrary, it is 
based on the recognition that failure to augment after 
vasodilatory challenge is an abnormal response. 
Allowing for a 5% variance in CBF measurements 
makes group 2 ( > 5% decrease) clearly a physiologi- 
cally abnormal group. The most hemodynamically 
compromised noninfarcted vascular territory was 
chosen to determine group classification• 
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Table II. Group characteristics 
Group 1 Group 2 
(N = 43) (N = 52) p Value 
History of stroke 19 29 0.306 
History of TIA 28 34 1.000 
Sex 
Male 32 34 
Female 11 18 0.378 
Mean age (yrs) 67.4 64.7 0.183 
T/A, transient ischemic attack. 
Statistical nalyses were performed with the SAS 
statistical package (SAS Institute Inc, Cary, N.C.). 
Cross tabulations and t tests were used to identify 
relationships among group classification, sex, age, 
type of angiographic lesion, medical history, and 
occurrence of subsequent s roke. Kaplan-Meier life 
table method was used to identify the cumulative 
stroke-free rate of the two groups. A value of 
p _< 0.05 was considered significant. 
RESULTS 
Sixteen patients had a documented new stroke 
during the follow-up period at a mean of 8 months 
after CBF measurement. Twelve (75%) of these 
strokes were ipsilateral to the region of least reactivity 
(Table I). 
In group I only one (2.3%) of 43 patients had a 
new stroke, but 15 (28.9%) of 52 patients had a 
stroke in group 2 (p = 0.0005). In those patients 
with total carotid occlusion, 10 (26%) of 38 in group 
2 and none (0%) of 26 in group 1 had a new stroke 
(p = 0.003). In those patients with greater than or 
equal to 70% stenosis, five (36%) of 14 in group 2 
and only one (6%) of 17 in group 1 had a stroke 
(p = 0.067). A Kaplan-Meier life table analysis 
shows a significant difference in stroke-free surcival 
rate between the two groups (Fig. 2) (p = 0.0004 by 
Mantel Cox statistic). 
Fig. 3 depicts the CBF studies in all 95 patients 
and illustrates the clustering of new strokes among 
the patients with poor vascular eactivity. All data 
points above the identity line represent patients in 
whom good reactivity with flow increases after ACZ 
challenge and a very low incidence of cerebral 
infarction were seen. 
Groups 1 and 2 were similar in age, sex, history 
of transient ischemic attack or stroke, and the 
presence of occlusion or stenosis (Table II). Baseline 
CBF was also similar between groups 1 and 2, with 
the response to ACZ being the only difference. 
Fourteen (87.5%) of 16 strokes occurred in patients 
with a baseline flow of greater than or equal to 30 
cc/100 grn brain/min (a level within normal range), 
and four of 16 strokes occurred in patients with 
greater than 50 cc/100 gm/min. 
Age, sex, history of transient ischemic attack or 
stroke, and degree of carotid stenosis were not 
significantly associated with the occurrence ofa new 
stroke. 
DISCUSSION 
Because of its relatively high metabolic rate and 
inability to store energy, the brain is critically 
dependent on adequate CBF to maintain metabolic 
needs. Multiple mechanisms exist for maintaining 
energy supplies despite severe occlusive disease. 
These mechanisms include autoregulation and in- 
creased oxygen extraction. 
The effect of CAOD on intracranial hemodynam- 
ics is variable depending on multiple factors includ- 
ing the patency of communicating arteries. 1° Al- 
though embolic events may be a common cause of 
cerebral infarction, the independent or synergistic 
effect of compromised hemodynamics on intensify- 
ing the associated ischemia is poorly defined. 
Currently available methods for assessing the 
cerebral circulation include noninvasive testing, 
which does yield useful information such as flow 
velocity in the extracranial (duplex scanning) or 
intracranial (transcranial Doppler) circulation, and 
the measurement of ocular blood pressure (oculo- 
plethysmography). 11,12 Angiographically defined 
anatomic information provides limited direct and 
indirect physiologic data such as cross-filling, patency 
of communicating arteries, and circulation time. 
Oculoplethysmography may be an indication of 
compromised cerebral reserves or collateral blood 
flow. Gee et al.13 compared preoperative and post- 
operative opthalmobrachial indexes in 516 patients 
with severe carotid stenosis undergoing carotid 
endarterectomy and found that 39% had limited 
collateral compensation. When collateral flow was 
inadequate a greater element of compensatory central 
hypertension was seen. We have compared Xe/CT 
CBF with oculoplethysmography ressures and have 
noted that a normal oculoplethysmography ressure 
suggests a given patient is tmlikely to have compro- 
mised CBF. 
Positron emission tomography (PET) studies 
have shown that impaired perfusion pressure l ads to 
vasodilatation a d reduced cerebrovascular resistance 
with an associated increase in cerebral blood volume. 
CBF remains normal (PET type I). 7,1° With further 
compromise, when maximal cerebral blood volume is 
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reached CBF becomes pressure-dependent, a d nor- 
real metabolism is maintained by increasing the 
oxygen extraction fraction (PET type II). This group 
of patients has diminished CBF and depends on the 
collateral network for oxygen delivery. The response 
to vasodilatory stimuli is exhausted, and some 
patients will show a decrease in local CBF, a "steal" 
phenomenon that has been associated with the 
dependence on leptomeningeal co laterals. 14'15 
The ability to directly measure CBF and the 
response to vasodilatory challenge should then offer 
valuable information regarding the net effect of 
extracranial and intracranial occlusive disease on 
regional cerebral vascular beds that have complex and 
variable collateral circulation and highly developed 
autoregulatory controls. Stable Xe/CT is easily avail- 
able, cost-effective, reproducible, quantitative, and 
provides accurate anatomic orrelation. Other mo- 
dalities of obtaining similar information suffer from 
supplying only qualitative data (single photon emis- 
sion computed tomography), from having poor 
resolution and no anatomic reference (133Xe CBF), or 
from having limited availabifity and considerable 
expense (PET). Transcranial Doppler scanning com- 
bined with ACZ challenge may prove to be a sensitive 
method of examining CBF reserves in the furore. 
During the past decade stable Xe/CT CBF 
mapping has been performed on more than 9000 
patients in our hospital. This mapping has included 
studies for many clinical diagnoses other than cere- 
brovascular disease. Substantial clinical experience 
has demonstrated that most patients with cerebrovas- 
cnlar disease have normal baseline CBF and normal 
reserves or reactivity. Currently the request for CBF 
mapping in any specific patient is a clinical decision 
made by the attending physician and is usually 
reserved for those patients in whom CBF might likely 
be abnormal based on past experience. Cerebral 
blood flow is most likely to be compromised in
patients with multiple extracranial rterial occlusive 
segments as determined by noninvasive t sting such 
as carotid duplex scanning or transcranial Doppler 
evaluation. Angiographic patterns of occlusion in- 
cluding absent communicating arteries may suggest a 
relatively isolated vascular territory or hemisphere. 
Smith et al.16 have recently correlated Xe/CT CBF 
and collateral flow patterns. A substantial discrepancy 
in ocular blood pressures may suggest inadequate 
collateral blood flow. This accounts in part for the 
relatively high number (group 2) of patients with 
abnormal results in this review. We do not believe 
that this random selection of patients for analysis 
influences the basic finding that those patients who 
have reduced reactivity are at substantial risk for 
stroke. 
The decision to stratify patients into two groups 
on the basis of no less than a 5% decrease inflow after 
vasodilatory challenge is arbitrary. In a previous 
report of the first 68 patients we used a different 
grouping system that also took into consideration the 
baseline CBF. 17 With more patients and longer 
follow-up periods, several new strokes appeared in 
patients with normal baseline values for CBF, high- 
lighting the predictive value of ACZ response as a 
single indicator. Thus the stratification was modified 
for this report but remains artificial. Although group 
1 contains all the patients with a normal response of 
flow augmentation in all territories, it also includes 
patients with mildly abnormal reactivity. Patients in 
group 2 are clearly the most severely compromised 
but are heterogeneous; some have more than one 
territory with greater than 5% reduction i  CBF after 
ACZ administration. This finding explains why some 
of the strokes were not in the index territory but were 
ipsilateral in adjacent areas. The only stroke in group 
I was in the contralateral hemisphere, which further 
suggested that it was not hemodynamic in nature. 
Our analysis is still evolving, and we hope to refine 
the classification with further experience to better 
define risk groups. 
A highly predictive dassification system based on 
vascular eactivity could become very important in 
selecting patients for revascularization in some con- 
troversial reas uch as asymptomatic carotid stenosis 
or extracranial-intracranial bypass for carotid occlu- 
sion. The extracranial-intracranial bypass study, 
which found no advantage to cerebral revasculariza- 
don, was conducted without evaluation or stratifica- 
tion based on any assessment of CBF status. 18 
Other means of stratifying patients regarding risk 
for stroke are potentially important. These include 
theologic factors such as viscosity (hematocrit, fi- 
brinogen levels, etc.) and systemic blood pressure 
control or cardiac arrhythmias. These factors could be 
included in the furore. We have not meant o imply 
that patients with symptoms who have greater than 
70% carotid stenosis, normal CBF, and normal 
response to vasodilation challenge (group 1) should 
not undergo carotid endarterectomy. Our cm-cent 
understanding of cerebrovascular disease would sug- 
gest that thromboembolic complications of carotid 
stenosis may occur in the absence of preexisting CBF 
abnormalities. 
Patients with symptomatic CAOD who have 
significantly compromised CBF vasoreacfivity even 
despite normal baseline CBF are at substantial risk for 
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stroke. Compromised  CBF reserves are an important  
determinant  o f  ischemic infarction probably  regard- 
less o f  whether  it is precipitated by embol ic  or 
hemodynamic  factors. New strategies for stroke 
prevention may include less aggressive management  
o f  hypertension and more aggressive cerebral revas- 
cularization in selected patients. 
Further  informat ion is clearly needed regarding 
the cause o f  stroke. The mere presence o f  single or 
mult ip le vessel occlusive disease alone is an inad- 
equate indicator o f  the risk o f  stroke. A greater 
understanding o f  the many factors that may ulti- 
mately influence the natural history o f  cerebrovascu- 
lar disease is necessary to reduce the incidence o f  
stroke but  at the same t ime reduce the morb id i ty  and 
morta l i ty  o f  potential ly unnecessary interventions. 
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DISCUSSION 
Dr. Eugene F. Bernstein (La Jolla, Calif.). President 
Fogarty, members, and guests: Drs. Webster, Makaroun, 
and their colleagues are to be complimented on this elegant 
presentation, which uses the stable xenon cerebral blood 
flow technology developed at the University of Pittsburgh 
in the past decade as a tool to measure the magnitude of 
impairment of cerebral arterial perfusion in a stroke-prone 
population. The method is sensitive, accurate, and repro- 
ducible. The results, which show that the more diseased 
patients have a much greater likelihood of furore stroke, are 
therefore not a surprise. However, the take-home for those 
of us who have not had access to this technology as yet is 
very important and should stimulate others to work on this 
problem with a variety of methods. In cases where the 
balance of risk and benefit of carotid surgical procedures i
close, these kind of data will help determine the correct 
course of management. 
I have four questions for the authors. The most obvious 
is whether more available and less expensive tests can 
provide equivalent information. Transcranial Doppler 
scanning, which examines the patency and direction of flow 
in all the branches of the circle of Willis, with which there 
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could also be a Diamox-like stimulated ilatation, would be 
the obvious candidate for comparison with their method. 
Have they any data comparing TCD with stable xenon? 
Other methods that might provide similar or even more 
valuable information include alternative indirect ultra- 
sonography tests, PET and SPECT scanning, and magnetic 
source imaging. Have any of these been compared with 
stable xenon? 
Second, I wondered what happened to those patients 
who were eliminated from this report because they 
underwent carotid surgical procedures. It would be par- 
ticularly impressive, if carotid endarterectomy corrected the 
regional flow deficits or significantly decreased the inci- 
dence of subsequent stroke. Can the authors tell us 
anything about his group of patients that they eliminated 
from the report? 
Third, why were these 31 patients with cerebral 
vascular symptoms and tight carotid stenoses not subjected 
to operation? Were there other factors that are pertinent to 
the discussion of defining their stroke risk that we should 
know about? 
And finally, do the authors have any comparable data 
in patients with asymptomatic stenosis where the risk- 
benefit balance in carotid surgical procedures i  closer, and 
these data might be critically important? 
Again, I would like to thank the authors for their 
stimulating contribution. They have identified a very 
important problem and offered us all a very reasonable tool 
towards its solution. 
Dr. Michel S. Makarotm. At present, this technology 
is very accessible through a package that can be added 
to any CT scanner. It includes both computer hardware 
and software and is not very expensive. The equipment 
costs less than a duplex scanner, and in our center it costs 
$300 to $400 per study and is not out of reach when 
compared with the studies performed with this type of 
disease. 
We do not have a direct comparison between TCD and 
xenon with the reactivity of CO 2 or Diamox. We do have 
correlation between the xenon CT cerebral blood flow 
study and the PET type I and II as determined by other 
investigators. There is a very good correlation between the 
patients with decreased cerebral blood flow reactivity and 
the PET scan type II, characterized by vasodilatation and 
increased cerebral blood volume. 
To come up with the 95 patients you were very 
perceptive to note that we must have eliminated a lot of 
other patients. We started with about 600 patients, and 
about 120 were eliminated because they had carotid 
endarterectomy after this test. We do not have follow-up 
information on all of the patients with the xenon cerebral 
blood flow study, but of those who do have some follow-up 
xenon cerebral blood flow, there has been a statistically- 
significant correction of the deficit. 
The 31 patients who were not operated on with a tight 
stenosis and a symptomatic lesion, most of them predate 
the NASCET trial. The treatment was determined entirely 
by the referring physician. 
We are following another group of asymptomatic 
patients. The numbers are still too small to be reported. 
Dr. Wesley S. Moore (Los Angeles, Calif.). This was 
a superb presentation. It is my understanding that all of the 
patients in the series were symptomatic, either with TIA or 
stroke. My question has to do with those individuals who 
fell into your group 1. It is my understanding that they did 
not have redistribution of blood flow upon stimulation and 
therefore presumably were not "maxed-out" as far as their 
collateral reserve was concerned. How do you suppose their 
symptoms occurred in the first place? 
Dr. Makaroun. We believe that cerebral symptoms 
occur both from atheroemboli and from superimposed 
hemodynamic parameters. We do not presume to explain 
-all cerebral symptoms on the basis of hemodynamic 
parameters. We are just trying to imply that the patients 
with decreased reserves tend to develop more strokes over 
the long term than do patients who do not have good 
reserves and therefore are in a higher risk category. 
Dr. Lazar J. Greenfield (Ann Arbor, Mich.). Did the 
strokes that occurred happen in the areas that you had 
identified as potentially ischemic? 
Dr. Makaroun. These are all detailed in the manu- 
script. Twelve of the 16 are ipsilateral to the territory of 
least reactivity, and nine are in the same territory identified. 
Dr. Samuel J. Williams (Roanoke, Va.). Rightly or 
wrongly, I usually have determined the safe timing of 
carotid endarterectomy after stroke based on the stability of 
the patient's neurologic examination combined with ap- 
pearance of the cerebral CT scan with contrast, and I have 
invariably come up with a 4- to 6-week wait. Could the 
modality ou described be helpful in this regard? 
Dr. Makarotm. I do not believe that this can predict 
the timing when it becomes afe to operate on patients, 
although we have recently stopped using the 4- to &week 
rule after several reports that show that when the patient is 
stable neurologically, ou can probably proceed with the 
endarterectomy. 
Dr. Nasir Shaikh (Pittsburgh, Pa.). Dr. Makaroun, 
there are patients who we follow who have been evaluated 
by their family practice doctors, and they have a tight 
stenosis of their internal carotid artery, either unilateral or 
bilateral, and they have been asymptomatic. Will this study 
help us to determine whether they should be operated or 
not because that is still controversial? 
Dr. Makaroun. We are very hopeful that this tech- 
nique will prove very useful in the questionable indications 
for carotid endarterectomy in the future. Unfortunately we 
do not have enough data yet to make those type of 
suggestions. 
